At J&J, Q3 Pharma Performance Is Up, Rest of Business Is Down
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts were disappointed in J&J's overall results, but the pharma sector performed well, driven by Remicade and new product sales.